Effects of Gastric Acid on Colonic Microbiome
Primary Purpose
Clostridium Difficile
Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Omeprazole 40 mg bid
Sponsored by
About this trial
This is an interventional basic science trial for Clostridium Difficile focused on measuring Proton Pump Inhibitors, Microbiome, Clostridium difficile
Eligibility Criteria
Inclusion Criteria:
- 18 or more years old
- Able to give informed consent
Exclusion Criteria:
- Use of systemic antibiotics within the past year
- Use of acid suppression medications (PPIs or H2-receptor antagonists) within the past year (antacids permitted if more than one month from date of enrollment)
- History of chronic gastrointestinal mucosal disease (e.g. inflammatory bowel disease, celiac disease, microscopic colitis)
- Any clinically significant or uncontrolled major morbidity, including but not limited to serious cardiac or respiratory disease or uncontrolled HIV
- Abnormal bowel frequency (minimum once every 2 days, maximum 3 times per day)
- Use of clopidogrel or medications with potential significant interaction with PPIs
- Osteoperosis or history of non-traumatic bone fracture
- History of adverse reactions to PPIs
- Initiation of any new medication within the month prior to enrollment
- Pregnancy
- Inability to give informed consent
Sites / Locations
- Columbia University
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Omeprazole 40 mg bid x 4-8 weeks
Arm Description
See study description for further details.
Outcomes
Primary Outcome Measures
Microbiome diversity
In order to assess the diversity of the colonic microbiome, three Bray-Curtis indices will be calculated for each subject:
After four weeks of no acid suppression (Week 0 vs. Week -4)
After four weeks of twice daily PPI (Week 4 vs. Week 0)
After 8 weeks of twice daily PPI or four weeks of "washout" (Week 8 vs. Week 4)
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01901276
Brief Title
Effects of Gastric Acid on Colonic Microbiome
Official Title
The Effects of Gastric Acid Suppression on the Colonic Microbiome
Study Type
Interventional
2. Study Status
Record Verification Date
April 2015
Overall Recruitment Status
Completed
Study Start Date
August 2013 (undefined)
Primary Completion Date
March 2015 (Actual)
Study Completion Date
March 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Daniel Freedberg
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The colonic microbiome is essential in human health and disease. Clostridium difficile-associated diarrhea (CDAD), a highly morbid form of infectious diarrhea, is caused by antibiotics which perturb the microbiome and allow C. difficile to proliferate. Proton pump inhibitors (PPIs) are powerful suppressors of gastric acid and among the most common medicines in the United States. Dozens of observational studies show that longterm PPI use is associated with CDAD. However, the mechanism by which PPIs cause CDAD is unknown. We believe that PPIs cause CDAD by inducing alterations in the human colonic microbiome. We will confirm or refute the hypothesized mechanism for the association between PPIs and CDAD using an unblinded, single-armed study design. We will use pyrosequencing of the hypervariable V4 region of the bacterial 16S ribosomal subunit gene in human fecal samples to describe the colonic flora. We will collect fecal samples from volunteers before and after PPIs given for different durations and test the microbiome to determine 1) whether PPIs diminish overall diversity, 2) whether PPIs diminish relative abundance of Bacteroidetes, 3) whether increased duration of PPIs affects diversity, and 4) whether there is recovery of diversity after completing a defined course of PPIs. We believe that PPIs will cause a pattern of diminished overall microbiome diversity and reduced anaerobes - the same pattern seen after use of antibiotics. Furthermore, we believe that increased PPI duration will further diminish diversity and that the microbiome will return to pre-PPI levels of diversity after PPIs are stopped. These results will facilitate biologically-based clinical interventions to reduce rates of CDAD among patients who require acid suppression.
Detailed Description
Study Design We will recruit 12 adult volunteers for a crossover study with a total duration of 12 weeks. Subjects will be observed off of PPIs for 4 weeks and then will be placed on PPIs for 4 weeks. Subsequently, subjects will be randomized to receive an additional 4 weeks of PPIs or no therapy. Stool samples will be collected at 4 separate time points.
Study Outcomes and Statistical Analyses The primary outcome will be change in overall diversity of fecal flora after 4 weeks of PPIs compared to 4 weeks of no acid suppression. Additional outcomes to be assessed include the effect of PPIs on the relative abundance of Bacteroidetes at week 4 and change in the diversity of fecal flora at week 8.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Clostridium Difficile
Keywords
Proton Pump Inhibitors, Microbiome, Clostridium difficile
7. Study Design
Primary Purpose
Basic Science
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
12 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Omeprazole 40 mg bid x 4-8 weeks
Arm Type
Experimental
Arm Description
See study description for further details.
Intervention Type
Drug
Intervention Name(s)
Omeprazole 40 mg bid
Other Intervention Name(s)
Brand name: Prilosec
Intervention Description
As above.
Primary Outcome Measure Information:
Title
Microbiome diversity
Description
In order to assess the diversity of the colonic microbiome, three Bray-Curtis indices will be calculated for each subject:
After four weeks of no acid suppression (Week 0 vs. Week -4)
After four weeks of twice daily PPI (Week 4 vs. Week 0)
After 8 weeks of twice daily PPI or four weeks of "washout" (Week 8 vs. Week 4)
Time Frame
4 weeks
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
18 or more years old
Able to give informed consent
Exclusion Criteria:
Use of systemic antibiotics within the past year
Use of acid suppression medications (PPIs or H2-receptor antagonists) within the past year (antacids permitted if more than one month from date of enrollment)
History of chronic gastrointestinal mucosal disease (e.g. inflammatory bowel disease, celiac disease, microscopic colitis)
Any clinically significant or uncontrolled major morbidity, including but not limited to serious cardiac or respiratory disease or uncontrolled HIV
Abnormal bowel frequency (minimum once every 2 days, maximum 3 times per day)
Use of clopidogrel or medications with potential significant interaction with PPIs
Osteoperosis or history of non-traumatic bone fracture
History of adverse reactions to PPIs
Initiation of any new medication within the month prior to enrollment
Pregnancy
Inability to give informed consent
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Julian A Abrams, MD, MS
Organizational Affiliation
Columbia University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Columbia University
City
New York
State/Province
New York
ZIP/Postal Code
10032
Country
United States
12. IPD Sharing Statement
Citations:
PubMed Identifier
26164495
Citation
Freedberg DE, Toussaint NC, Chen SP, Ratner AJ, Whittier S, Wang TC, Wang HH, Abrams JA. Proton Pump Inhibitors Alter Specific Taxa in the Human Gastrointestinal Microbiome: A Crossover Trial. Gastroenterology. 2015 Oct;149(4):883-5.e9. doi: 10.1053/j.gastro.2015.06.043. Epub 2015 Jul 9.
Results Reference
derived
Learn more about this trial
Effects of Gastric Acid on Colonic Microbiome
We'll reach out to this number within 24 hrs